VA-REGULA-FORENSICS
8.6.2021 14:02:08 CEST | Business Wire | Press release
Permission.io, the digital advertising platform that lets online marketers reward users for interacting with ads, announces the integration with the Regula Document Reader SDK to cover the full know-your-customer (KYC) process. The partnership mitigates the risk of fraud and delivers a verified audience to advertisers.
Regula is a global software and hardware manufacturer focused on the verification of identity documents, banknotes, and securities. With 28 years of experience, Regula is a trusted name to experts in both the private and public sectors worldwide. The company has the industry’s largest database of document templates and uses artificial intelligence to automatically determine document type and reveal the visual signs of fraud. Proprietary Face Matching and Liveness Detection technologies make Regula a one-stop solution for identity verification.
Permission.io is a digital advertising platform that enables consumers to earn rewards for interacting with advertisements. The company uses blockchain technology to allow advertisers to reward consumers with ASK, the platform’s native digital currency, for signing up, providing profile and preference data, engaging with video ads, referring friends, and other activities.
“Digital Advertising is ripe for a change,” said Charles Silver, CEO of Permission.io . “Big tech exploits user data, and click fraud is estimated to grow into an $87 billion business in 2021. The major platforms grade their own homework, so to speak, and advertisers are getting the short end of the stick. Too often, the ads they pay to deliver are not even being seen. Permission is bringing the change this industry needs by respecting user data and by delivering to advertisers superior targeting and better ROI on their considerable spend.”
“Financial technology needs the most secure protection from fraud, and we’re happy to share our expertise in document forensics with emerging industry leaders to ensure clear and reliable fraud detection while onboarding and asset management,” said Arif Mamedov, President of Regula Forensics Inc . “Our web and mobile products have been designed to meet the requirements of fintech and to be seamlessly integrable into any scenario and interface.”
Regula Document Reader SDK parses documents and extracts personal data, eliminating manual data input and minimizing mistakes. When it comes to data validation, Regula’s technology cross-checks the data obtained from MRZ, VIZ, and barcodes. The process of user identification is completed with face matching in seconds, while the personal data is secured by the internal Permission network. “We are very excited to add Regula's invaluable expertise to our promise to prevent identity fraud and deliver a delightful user experience,” Silver said.
About Regula Forensics:
Regula is a global software and hardware manufacturer focused on the verification of identity documents, banknotes, and securities. Regula’s software product suite includes ID verification, facematching and liveness technologies for mobile applications and web-based solutions, to build a seamless on-premises digital identity and biometric verification workflow.
135 international borders are equipped with Regula hardware and software products. Regula is an official partner of the UN, Interpol, OSCE, IATA and ICAO. For more information, visit https://mobile.regulaforensics.com .
About Permission.io:
Permission.io is the leading platform for permission advertising for eCommerce. The company has created the ASK digital currency to enable individuals to securely grant permission and monetize their data on Permission.io and 3rd-party e-commerce platforms. Advertisers reward consumers with ASK for interacting with brands and content, building trust, and increasing ROI. To learn more, visit https://permission.io .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210608005012/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom